亚洲精品1234,久久久久亚洲国产,最新久久免费视频,我要看一级黄,久久久性色精品国产免费观看,中文字幕久久一区二区三区,久草中文网

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

Initial clinical trial shows CoronaVac vaccine safe for children, adolescents: study

Xinhua | Updated: 2021-06-29 14:04
Share
Share - WeChat
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing, March 16, 2020. [Photo/Xinhua]

LONDON - Phase 1/2 clinical trial of the CoronaVac COVID-19 vaccine in over 500 children and adolescents suggests two doses of the vaccine are safe and generate a strong antibody response, according to a study published Monday in The Lancet Infectious Diseases journal.

Chinese researchers conducted a randomized, double-blind, controlled phase 1/2 clinical trial of the CoronaVac COVID-19 vaccine, developed by Chinese pharmaceutical company Sinovac Biotech, in more than 500 healthy children and adolescents aged three to 17 years in China.

The results showed that more than 96 percent of children and adolescents who received two doses of the vaccine in the trial developed antibodies against the novel coronavirus (SARS-CoV-2), the study said.

Most adverse reactions were mild or moderate, with pain at the injection site, the most commonly reported symptom, according to the study.

But the researchers also said that, owing to the small number of participants in the study, the results should be interpreted with caution as it was not possible to draw strong statistical conclusions.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US